Ovensa Inc.

Ovensa Inc. is a Canadian biotechnology startup founded in 2012 with a focus on advancing siRNA lead candidate to silence galectin-1 overexpression in the tumor microenvironment. Their main goal is to enhance the therapeutic outcomes of immuno-oncology anti-PD-1 checkpoint inhibitor as a combination therapy in head & neck cancer. Additionally, the company is actively involved in collaboration programs with pharmaceutical companies to develop precision and combination medicines using its proprietary TRIOZAN™ Platform. Ovensa operates in the Biotechnology and Health and Wellness industries, positioning itself at the forefront of innovative cancer therapeutics within the Canadian market. Despite not having publicly disclosed its last investment round or the involved investors, the company's dedication to advancing cancer therapies through precision medicine and combination therapies makes it an intriguing prospect for potential investors and stakeholders in the biotech landscape.